AMSBIO announce a new HER2 control cell line array

AMSBIO announce a new HER2 control cell line array that was developed and is proven as an effective slide quality control for HER2 expression in breast cancer tissue samples.

This new FFPE cell pellet microarray delivers a full dynamic range of HER2, ER and PR expression, validated by the Ventana system, to give immunohistochemical data in strong concordance with the routinely processed tissue sample.sections.

Using cell line controls significantly lower the costs of immunohistochemical (IHC) examinations and fluorescence in situ hybridization (FISH) while enabling high levels of standardization and reliability. The new HER2 cell line microarray is perfect for cancer research establishments and laboratories that require results whilst not compromising on consistency or quality.

AMSBIO offer a wide range of high quality FFPE cancer cell line controls for your research. Manufactured using a proprietary process that maintains both cell morphology and preserves nucleic acids and proteins, the AMSBIO range of FFPE cancer cell line products offer affordable and consistent controls from 100 tumor cell lines, without compromising quality or consistency. These cell line controls combat issues experienced with traditional cell or tissue-based control specimens such as intra specimen variation, lot-to-lot variations and inconsistent biomolecule quality. FFPE controls provide the most flexible cell-based products for immunohistochemistry , in situ hybridization and next generation screening applications.

For further information on the new HER2 control tissue microarray for breast cancer clinical testing please visit or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 /

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.

Media Contact Information: 

Dr Bill Bradbury